tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

AMGN Stock Latest News

Amgen’s New Clinical Trial: A Potential Game-Changer in Autoimmune Disease Treatment
Company AnnouncementsAmgen’s New Clinical Trial: A Potential Game-Changer in Autoimmune Disease Treatment
4d ago
AMGN
Amgen’s Promising Study on Romosozumab for Osteogenesis Imperfecta
PremiumCompany Announcements
Amgen’s Promising Study on Romosozumab for Osteogenesis Imperfecta
4d ago
AMGN
Amgen price target raised to $272 from $261 at BofA
PremiumThe Fly
Amgen price target raised to $272 from $261 at BofA
5d ago
AMGN
Amgen’s Rocatinlimab Study: A Potential Game-Changer for Atopic Dermatitis
PremiumCompany Announcements
Amgen’s Rocatinlimab Study: A Potential Game-Changer for Atopic Dermatitis
5d ago
AMGN
Amgen’s CodeBreaK 202: A Promising Study in Lung Cancer Treatment
PremiumCompany Announcements
Amgen’s CodeBreaK 202: A Promising Study in Lung Cancer Treatment
5d ago
AMGN
Amgen’s Promising Phase 3 Study on Avacopan for Pediatric AAV
PremiumCompany AnnouncementsAmgen’s Promising Phase 3 Study on Avacopan for Pediatric AAV
5d ago
AMGN
Amgen and AstraZeneca’s HORIZON Study: A New Hope for Pediatric Asthma
Premium
Company Announcements
Amgen and AstraZeneca’s HORIZON Study: A New Hope for Pediatric Asthma
5d ago
AZN
AMGN
Amgen’s AMG 193 Study: A New Hope for Advanced NSCLC
Premium
Company Announcements
Amgen’s AMG 193 Study: A New Hope for Advanced NSCLC
5d ago
AMGN
Amgen’s Promising Phase 3 Study: Tarlatamab and Durvalumab in Lung Cancer
PremiumCompany Announcements
Amgen’s Promising Phase 3 Study: Tarlatamab and Durvalumab in Lung Cancer
5d ago
AMGN
Amgen’s Promising Cardiovascular Study: A Potential Game-Changer?
PremiumCompany Announcements
Amgen’s Promising Cardiovascular Study: A Potential Game-Changer?
5d ago
AMGN
Amgen’s MARITIME-2 Study: A Potential Game-Changer in Diabetes Treatment
PremiumCompany Announcements
Amgen’s MARITIME-2 Study: A Potential Game-Changer in Diabetes Treatment
5d ago
AMGN
Amgen’s Promising Phase 3 Study on Dazodalibep for Sjögren’s Syndrome
PremiumCompany Announcements
Amgen’s Promising Phase 3 Study on Dazodalibep for Sjögren’s Syndrome
5d ago
AMGN
Amgen’s Promising Obesity Treatment Study: Key Insights for Investors
PremiumCompany AnnouncementsAmgen’s Promising Obesity Treatment Study: Key Insights for Investors
5d ago
AMGN
Amgen’s New Melanoma Study: A Potential Game-Changer in Cancer Treatment?
Premium
Company Announcements
Amgen’s New Melanoma Study: A Potential Game-Changer in Cancer Treatment?
5d ago
AMGN
Amgen’s New Study: A Potential Game-Changer in Lung Cancer Treatment?
Premium
Company Announcements
Amgen’s New Study: A Potential Game-Changer in Lung Cancer Treatment?
5d ago
AMGN
Amgen’s Dazodalibep Study: A Potential Game-Changer for Sjögren’s Syndrome
PremiumCompany Announcements
Amgen’s Dazodalibep Study: A Potential Game-Changer for Sjögren’s Syndrome
5d ago
AMGN
BeOne Medicines price target raised to $360 from $334 at TD Cowen
PremiumThe Fly
BeOne Medicines price target raised to $360 from $334 at TD Cowen
5d ago
ONC
AMGN
Viridian Therapeutics price target raised to $32 from $28 at Oppenheimer
PremiumThe Fly
Viridian Therapeutics price target raised to $32 from $28 at Oppenheimer
6d ago
AMGN
VRDN
Amgen’s Underperform Rating: Concerns Over R&D Expenses and Trial Strategy Impacting Future Growth
PremiumRatings
Amgen’s Underperform Rating: Concerns Over R&D Expenses and Trial Strategy Impacting Future Growth
6d ago
AMGN
Amgen’s Q2 FY 2025 Earnings: Strong Growth and Promising Future
PremiumCompany AnnouncementsAmgen’s Q2 FY 2025 Earnings: Strong Growth and Promising Future
6d ago
AMGN
Amgen sees MariTide Type 2 diabetes readout in Q4
Premium
The Fly
Amgen sees MariTide Type 2 diabetes readout in Q4
6d ago
AMGN
Amgen: Strong Financial Performance and Promising Growth Prospects Drive Buy Rating
Premium
Ratings
Amgen: Strong Financial Performance and Promising Growth Prospects Drive Buy Rating
7d ago
AMGN

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >